Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | P2RY1 | P47900 | 2/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24511426 | 0.84 | SAT1 (0.36) | DRD2HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL23806436 | 0.84 | DRD2 (0.37) | DRD2HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL22856429 | 0.84 | DRD2 (0.37) | DRD2HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL22526292 | 0.84 | CARM1 (0.39) | DRD2HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL23696009 | 0.83 | SIGMAR1 (0.36) | DRD2HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL23945437 | 0.83 | DRD2 (0.36) | DRD2HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL23572087 | 0.81 | HRH3 (0.36) | DRD2HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL23945990 | 0.81 | CHRM4 (0.37) | HRH3CHRM4CYP2D6KCNH2 | |
| SCHEMBL22526285 | 0.80 | CARM1 (0.40) | DRD2HTR2AHTR2CHTR2BSIGMAR1 | |
| SCHEMBL21107631 | 0.79 | DRD2 (0.39) | DRD2HTR2AHTR2CHTR2BSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11807636-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11779578-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-09-28 | — | — | US | disclosed |
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2022-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220340570-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | DRD2 4346/4885HTR2A 3621/4885HTR2C 4114/4885 |
| US-11807636-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | DRD2 4346/4885HTR2A 3621/4885HTR2C 4114/4885 |
| US-20230303526-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | DRD2 4346/4885HTR2A 3621/4885HTR2C 4114/4885 |
| US-11779578-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | DRD2 4346/4885HTR2A 3621/4885HTR2C 4114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.